Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2497172 | 0.99 | DRD4 (0.44) | DRD4CCR3SIGMAR1CCR2KCNH2 | |
| SCHEMBL1811847 | 0.95 | DRD4 (0.39) | DRD4CCR3SIGMAR1 | |
| SCHEMBL1811582 | 0.94 | DRD4 (0.47) | DRD4CCR3SIGMAR1 | |
| SCHEMBL1812511 | 0.93 | DRD4 (0.47) | DRD4SIGMAR1 | |
| SCHEMBL1810279 | 0.93 | CCR3 (0.44) | DRD4CCR3SIGMAR1CCR2KCNH2 | |
| SCHEMBL1810421 | 0.93 | DRD4 (0.42) | DRD4 | |
| Potassium Ion SCHEMBL2497164 | 0.92 | DRD4 (0.42) | DRD4CCR3SIGMAR1CCR2KCNH2 | |
| SCHEMBL1805700 | 0.92 | DRD4 (0.40) | DRD4CCR3SIGMAR1 | |
| SCHEMBL1809087 | 0.92 | DRD4 (0.50) | DRD4SIGMAR1 | |
| SCHEMBL1805899 | 0.91 | DRD4 (0.44) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | claimed |
| EP-2042499-B1 | SALT OF A MORPHOLINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | claimed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | claimed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | claimed |
| EP-2042499-A1 | SALT OF MORPHOLINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-01 | — | — | EP | claimed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | claimed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2020203822-A1 | COMBINED DRUG FOR TREATING OR PREVENTING RETINAL DISEASE ASSOCIATED WITH ANGIOGENESIS | 千寿製薬株式会社 | 2020-10-08 | — | — | WO | disclosed |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| EP-2042499-B1 | SALT OF A MORPHOLINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090264430-A1 | Salt of morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-2042499-A1 | SALT OF MORPHOLINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008007691-A1 | SALT OF MORPHOLINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-17 | — | — | WO | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | CCR3, CCR1, CCRL2 | DRD4 1971/4885CCR3 1/4885SIGMAR1 3739/4885 |
| US-20090264430-A1 | Salt of morpholine compound | SLC11A2, SLC16A7, AVPR2 | DRD4 582/4885CCR3 4068/4885SIGMAR1 108/4885 |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | DRD4 3410/4885CCR3 3110/4885SIGMAR1 2072/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | DRD4 3410/4885CCR3 3110/4885SIGMAR1 2072/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | DRD4 768/4885CCR3 1/4885SIGMAR1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.